

GlycanAge

Our vision is to make **preventive & personalized healthcare** the standard of care

In collaboration with:



As seen on:




We live longer than ever before and yet **spend** more than **50% of our lives in poor health**

We have made tremendous gains in **Lifespan**, but our **Healthspan** hasn't improved over the last 60 years

Life expectancy 1960 – **54 years**




Life expectancy 2019 – **73 years**



 Time spent in poor or declining health

Chronic inflammation is the leading contributor of poor health, leading to 3/5 deaths worldwide

Diseases born out of chronic inflammation of the immune system **kill 37 million** people each year



As the world continues to **get older**, chronic diseases will become an **unsustainable burden**

Healthcare costs associated with combatting chronic disease have **increased 4.3x** over the past 20 years and will continue to rise to a staggering **12.6% of Global GDP** by 2050


2.1 billion

People worldwide will be **over the age of 60** by 2050

80%

Of adults over 60 suffer from **at least 1 chronic condition**


Costs of managing Chronic Disease:



[CDC Report](#) on chronic disease cost impact

What are Glycans and why are they **the future of preventative healthcare?**

What are Glycans?



- 1 Glycans are complex sugar molecules that coat every cell in the human body
- 2 They regulate immune function, inflammation, and cellular communication,
- 3 Unlike DNA, glycans change dynamically in response to lifestyle, stress, and medical interventions,

Glycans have **the power to predict** chronic diseases up to **10 years** in advance

Pathology	Model Parameters	Accuracy	Prediction	Study
Menopause	IgG glycans + Age	AUC 0.85	n/a	Deris et al, iScience, 2022
Hypertension	IgG glycans / glycan traits	AUC 0.983	6.3y	Kifer et al, J Hypertens, 2021
Cardiovascular and cerebrovascular events (M=men, W=women)	plasma glycans + AHA score	(M) AUC 0.72	8.3y	Wittenbecher et al, Diabetes Care, 2020
	plasma glycans + AHA score	(W) AUC 0.77	8.3y	Wittenbecher et al, Diabetes Care, 2020
	IgG glycans	(M) HR 1.6	8.3y	Birukov et al, Diabetes Care, 2022
	IgG glycans	(W) HR 0.74	8.3y	Birukov et al, Diabetes Care, 2022
Type 2 Diabetes	plasma glycans + GDRS	AUC 0.9	6.5y	Wittenbecher et al, Diabetes Care, 2020
	plasma glycans + BMI	AUC 0.78	7.1y	Cvetko et al, BMJ Open Diab Res Care, 2021
	IgG glycans	HR 1.21-1.49	6.5y	Birukov et al, Diabetes Care, 2022
Insulin Resistance	plasma glycans + BMI	AUC 0.78	7.1y	Cvetko et al, BMJ Open Diab Res Care, 2021
Crohn's Disease	IgG glycans	AUC 0.77	4.3y	Gudelj et al, Bioch Biophys Acta Mol Basis, 2018 Sebastian et al, OMICS, 2016
Rheumatoid Arthritis	IgG glycans	AUC 0.928	6.0y	Gaifem et al, Nature Immunology, 2024

Who are we?

We have been studying aging for the past 30 years, publishing our findings in more than 300 scientific papers, some of which in collaboration with world renowned research and education institutions.

GlycanAge at a glance:

+300,000

Glycan samples analyzed
by our lab to date

€40m

In R&D grant funding from
various entities

+300

Peer reviewed scientific
publications

+900

Partner clinics and providers
around the world

63

Countries reached around
the world

+30

Years of scientific and
academic research



HARVARD
MEDICAL SCHOOL



JOHNS HOPKINS
UNIVERSITY



UNIVERSITY OF
OXFORD



UNIVERSITY OF
CAMBRIDGE



Yale University

KING'S
College
LONDON

ScienceAdvances

nature
COMMUNICATIONS

Circulation

International
Journal of Obesity

To learn more, visit glycanage.com/publications

GlycanAge

We are pioneers in the Glycan space with a wide competitive moat

GlycanAge is the **only commercially available glycomics-based test**, providing unmatched insights into health and longevity.

1 Unrivaled Capabilities

The world's **only high-throughput glycomics lab**, analysing 80% of global glycan samples with unmatched precision and scalability.

2 Patented IP

Patents and proprietary technology covering aging, diabetes, menopause, and cardiovascular risk.

3 Robust R&D Pipeline

An R&D pipeline with **70+ potential indications**, expanding into oncology, autoimmune diseases, metabolic disorders, etc.

4 Technical Superiority

Stable, reproducible results with higher specificity compared to traditional epigenetic tests.

We build commercially viable longevity

We have delivered actionable health insights to more than 20,000 individuals in +60 countries around the world

Our Story in numbers:

+600

Partners clinics

+25,000

Tests Sold

\$1.8m

LTM Revenue

45%

Repeat Purchase
Rate

62%

Gross
Margin


\$6.2m

Commercial
Pipeline


Financial Performance Snapshot Q2 2025

Revenue growth has been accelerating, and the net income loss had narrowed as we have implemented stricter cost control measures

Revenue Growth:




Q2 Key Figures:



Strategic Vision of the Future

Moving out of the pure longevity and into diagnostics is how we will unlock **our next 100X growth** phase and reach millions of clients



Product Roadmap & Strategy

This year already we have made substantial progress into moving out of the pure longevity and into diagnostic applications

General Health/Longevity

- GlycanAge test on the market for the past 3 years
- **+600 partners** already using the product in their practice
- New upgraded, more comprehensive and actionable report to **launch in Q2 2025**

Weight Loss & GLP1

- 2 studies conducted; Patent application pending
- **Collaboration with Novo Nordisk** on companion diagnostic
- Currently recruiting partner clinics for pilot projects



2025

Hormone Optimization

- 6 studies conducted and papers published; One patent
- 20 pilots underway with hormone optimization and longevity clinics
- Soft launch of the new hormone optimization offering in Q3 2025 (**waiting list to launch in Q2 2025**)

Research Pipeline

- Research pipeline covering Cardio, Fertility, Autoimmune Disease
- **30 research projects** in progress funded by \$6.5m of grants
- Ongoing collaboration with +20 institutes/universities



2026

Our Management Team

Our team has more than **+100 years combined experience** in bringing to market scientific advancements in the healthcare and diagnostic sectors



Dr Gordan Lauc
Founder & CSO (**father**)

Founder of Genos, Professor of Biochemistry & Molecular Biology at the University of Zagreb. Hon. Prof at King's College London. Johns Hopkins Scholar. Co-authored **over 300 research papers, cited 18,300 times** with a H-index of 72, he is the 2nd most highly ranked glycobiochemist in the world.



Nikolina Lauc
Founder & CEO (**daughter**)

Serial entrepreneur with 15 years experience. Co-founder of several startups in the field of SaaS, travel and consumer health, scaling them to 30M in value. Co-inventor of a patent in Women's health diagnostics space. Recognized as the Entrepreneur of the Year 2023 in Croatia.



Zorrie Dimitrova
COO



Martin Iliev
CFO



Vladi Mihaylova
CMO



Marko Tarnaj
CPO



Paula Francekovic
Head of Education



Dr. Simisola Oke
Medical Advisor



Cameron Reynolds
Chairman of the Board



Dr. Diane Seimetz
Board Member

GlycanAge Series A round

We are looking for a **\$5m investment** to bring new products like **HRT optimization and other diagnostics** to market and unlock further growth

2023 Seed Fundraise

\$16m

Seed Pre-money
Valuation

\$4.1m

Total Funding
to Date



Current Round

\$30m

Series A Pre-money
Valuation

75%

Of funding secured from
new and existing investors

Backed by:

